Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBIT: 2023-2025

Historic EBIT for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$33.0 million.

  • Monte Rosa Therapeutics' EBIT fell 24.31% to -$33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 106.60%. This contributed to the annual value of -$81.1 million for FY2024, which is 43.40% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' EBIT is -$33.0 million, which was down 112.00% from -$15.6 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' EBIT peaked at $44.0 million during Q1 2025, and registered a low of -$37.2 million during Q2 2023.
  • Its 3-year average for EBIT is -$20.8 million, with a median of -$33.0 million in 2025.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' EBIT showed a top increase of 226.01% in 2025 and a maximum decrease of 24.31% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' EBIT (Quarterly) stood at -$34.9 million in 2023, then surged by 137.30% to $13.0 million in 2024, then dropped by 24.31% to -$33.0 million in 2025.
  • Its EBIT stands at -$33.0 million for Q3 2025, versus -$15.6 million for Q2 2025 and $44.0 million for Q1 2025.